1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Monoclonal Antibodies 1.2.3 Checkpoint Inhibitors 1.2.4 Oncoloytic Viral Therapies and Cancer Vaccines 1.3 Market by Application 1.3.1 Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Lung Cancer 1.3.3 Breast Cancer 1.3.4 Colorectal Cancer 1.3.5 Melanoma 1.3.6 Prostate Cancer 1.3.7 Head and neck Cancer 1.3.8 Ovarian Cancer 1.3.9 Pancreatic Cancer 1.3.10 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Oncolytic Virus Cancer Immunotherapy Market Perspective (2016-2027) 2.2 Oncolytic Virus Cancer Immunotherapy Growth Trends by Regions 2.2.1 Oncolytic Virus Cancer Immunotherapy Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Share by Regions (2016-2021) 2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Regions (2022-2027) 2.3 Oncolytic Virus Cancer Immunotherapy Industry Dynamic 2.3.1 Oncolytic Virus Cancer Immunotherapy Market Trends 2.3.2 Oncolytic Virus Cancer Immunotherapy Market Drivers 2.3.3 Oncolytic Virus Cancer Immunotherapy Market Challenges 2.3.4 Oncolytic Virus Cancer Immunotherapy Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue 3.1.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue (2016-2021) 3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2016-2021) 3.2 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Oncolytic Virus Cancer Immunotherapy Revenue 3.4 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio 3.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2020 3.5 Oncolytic Virus Cancer Immunotherapy Key Players Head office and Area Served 3.6 Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service 3.7 Date of Enter into Oncolytic Virus Cancer Immunotherapy Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Type 4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2016-2021) 4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2022-2027) 5 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application 5.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Application (2016-2021) 5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2016-2027) 6.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type 6.2.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) 6.2.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) 6.2.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2027) 6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application 6.3.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) 6.3.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) 6.3.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2027) 6.4 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country 6.4.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021) 6.4.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2016-2027) 7.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type 7.2.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) 7.2.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) 7.2.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2027) 7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application 7.3.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) 7.3.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) 7.3.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2027) 7.4 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country 7.4.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021) 7.4.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size (2016-2027) 8.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type 8.2.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2027) 8.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application 8.3.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2027) 8.4 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region 8.4.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size (2016-2027) 9.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type 9.2.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) 9.2.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) 9.2.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2027) 9.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application 9.3.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) 9.3.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) 9.3.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2027) 9.4 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country 9.4.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021) 9.4.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size (2016-2027) 10.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type 10.2.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2027) 10.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application 10.3.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2027) 10.4 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country 10.4.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 AstraZeneca 11.1.1 AstraZeneca Company Details 11.1.2 AstraZeneca Business Overview 11.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction 11.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.1.5 AstraZeneca Recent Development 11.2 Amgen 11.2.1 Amgen Company Details 11.2.2 Amgen Business Overview 11.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction 11.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.2.5 Amgen Recent Development 11.3 F Hoffman-La Roche 11.3.1 F Hoffman-La Roche Company Details 11.3.2 F Hoffman-La Roche Business Overview 11.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction 11.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.3.5 F Hoffman-La Roche Recent Development 11.4 Bristol-Myers Squibb 11.4.1 Bristol-Myers Squibb Company Details 11.4.2 Bristol-Myers Squibb Business Overview 11.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction 11.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.4.5 Bristol-Myers Squibb Recent Development 11.5 Novartis AG 11.5.1 Novartis AG Company Details 11.5.2 Novartis AG Business Overview 11.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction 11.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.5.5 Novartis AG Recent Development 11.6 Merck & Co., Inc. 11.6.1 Merck & Co., Inc. Company Details 11.6.2 Merck & Co., Inc. Business Overview 11.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction 11.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.6.5 Merck & Co., Inc. Recent Development 11.7 Pfizer 11.7.1 Pfizer Company Details 11.7.2 Pfizer Business Overview 11.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction 11.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.7.5 Pfizer Recent Development 11.8 Biovex 11.8.1 Biovex Company Details 11.8.2 Biovex Business Overview 11.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction 11.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.8.5 Biovex Recent Development 11.9 Cell Genesys 11.9.1 Cell Genesys Company Details 11.9.2 Cell Genesys Business Overview 11.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction 11.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.9.5 Cell Genesys Recent Development 11.10 Crusade Laboratories 11.10.1 Crusade Laboratories Company Details 11.10.2 Crusade Laboratories Business Overview 11.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction 11.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.10.5 Crusade Laboratories Recent Development 11.11 Genelux Corporation 11.11.1 Genelux Corporation Company Details 11.11.2 Genelux Corporation Business Overview 11.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction 11.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.11.5 Genelux Corporation Recent Development 11.12 Lokon Pharma 11.12.1 Lokon Pharma Company Details 11.12.2 Lokon Pharma Business Overview 11.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction 11.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.12.5 Lokon Pharma Recent Development 11.13 MultiVir 11.13.1 MultiVir Company Details 11.13.2 MultiVir Business Overview 11.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction 11.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) 11.13.5 MultiVir Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Monoclonal Antibodies Table 3. Key Players of Checkpoint Inhibitors Table 4. Key Players of Oncoloytic Viral Therapies and Cancer Vaccines Table 5. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 6. Global Oncolytic Virus Cancer Immunotherapy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 7. Global Oncolytic Virus Cancer Immunotherapy Market Size by Regions (2016-2021) & (US$ Million) Table 8. Global Oncolytic Virus Cancer Immunotherapy Market Share by Regions (2016-2021) Table 9. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 10. Global Oncolytic Virus Cancer Immunotherapy Market Share by Regions (2022-2027) Table 11. Oncolytic Virus Cancer Immunotherapy Market Trends Table 12. Oncolytic Virus Cancer Immunotherapy Market Drivers Table 13. Oncolytic Virus Cancer Immunotherapy Market Challenges Table 14. Oncolytic Virus Cancer Immunotherapy Market Restraints Table 15. Global Oncolytic Virus Cancer Immunotherapy Revenue by Players (2016-2021) & (US$ Million) Table 16. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players (2016-2021) Table 17. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2020) Table 18. Ranking of Global Top Oncolytic Virus Cancer Immunotherapy Companies by Revenue (US$ Million) in 2020 Table 19. Global 5 Largest Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue (CR5 and HHI) & (2016-2021) Table 20. Key Players Headquarters and Area Served Table 21. Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service Table 22. Date of Enter into Oncolytic Virus Cancer Immunotherapy Market Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) (US$ Million) Table 25. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2016-2021) Table 26. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2022-2027) (US$ Million) Table 27. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2022-2027) & (US$ Million) Table 28. Global Oncolytic Virus Cancer Immunotherapy Market Size Share by Application (2016-2021) & (US$ Million) Table 29. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2016-2021) Table 30. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2022-2027) (US$ Million) Table 31. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2022-2027) & (US$ Million) Table 32. North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) (US$ Million) Table 33. North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) & (US$ Million) Table 34. North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) (US$ Million) Table 35. North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) & (US$ Million) Table 36. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021) & (US$ Million) Table 37. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027) & (US$ Million) Table 38. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) (US$ Million) Table 39. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) & (US$ Million) Table 40. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) (US$ Million) Table 41. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) & (US$ Million) Table 42. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021) & (US$ Million) Table 43. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027) & (US$ Million) Table 44. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) (US$ Million) Table 45. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) & (US$ Million) Table 46. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) (US$ Million) Table 47. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) & (US$ Million) Table 48. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2016-2021) & (US$ Million) Table 49. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2022-2027) & (US$ Million) Table 50. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) (US$ Million) Table 51. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) & (US$ Million) Table 52. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) (US$ Million) Table 53. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) & (US$ Million) Table 54. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021) & (US$ Million) Table 55. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027) & (US$ Million) Table 56. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2016-2021) (US$ Million) Table 57. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2022-2027) & (US$ Million) Table 58. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2016-2021) (US$ Million) Table 59. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2022-2027) & (US$ Million) Table 60. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2016-2021) & (US$ Million) Table 61. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2022-2027) & (US$ Million) Table 62. AstraZeneca Company Details Table 63. AstraZeneca Business Overview Table 64. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product Table 65. AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 66. AstraZeneca Recent Development Table 67. Amgen Company Details Table 68. Amgen Business Overview Table 69. Amgen Oncolytic Virus Cancer Immunotherapy Product Table 70. Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 71. Amgen Recent Development Table 72. F Hoffman-La Roche Company Details Table 73. F Hoffman-La Roche Business Overview Table 74. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product Table 75. F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 76. F Hoffman-La Roche Recent Development Table 77. Bristol-Myers Squibb Company Details Table 78. Bristol-Myers Squibb Business Overview Table 79. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product Table 80. Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 81. Bristol-Myers Squibb Recent Development Table 82. Novartis AG Company Details Table 83. Novartis AG Business Overview Table 84. Novartis AG Oncolytic Virus Cancer Immunotherapy Product Table 85. Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 86. Novartis AG Recent Development Table 87. Merck & Co., Inc. Company Details Table 88. Merck & Co., Inc. Business Overview Table 89. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Product Table 90. Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 91. Merck & Co., Inc. Recent Development Table 92. Pfizer Company Details Table 93. Pfizer Business Overview Table 94. Pfizer Oncolytic Virus Cancer Immunotherapy Product Table 95. Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 96. Pfizer Recent Development Table 97. Biovex Company Details Table 98. Biovex Business Overview Table 99. Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 100. Biovex Recent Development Table 101. Cell Genesys Company Details Table 102. Cell Genesys Business Overview Table 103. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product Table 104. Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 105. Cell Genesys Recent Development Table 106. Crusade Laboratories Company Details Table 107. Crusade Laboratories Business Overview Table 108. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product Table 109. Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 110. Crusade Laboratories Recent Development Table 111. Genelux Corporation Company Details Table 112. Genelux Corporation Business Overview Table 113. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product Table 114. Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 115. Genelux Corporation Recent Development Table 116. Lokon Pharma Company Details Table 117. Lokon Pharma Business Overview Table 118. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product Table 119. Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 120. Lokon Pharma Recent Development Table 121. MultiVir Company Details Table 122. MultiVir Business Overview Table 123. MultiVir Oncolytic Virus Cancer Immunotherapy Product Table 124. MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) & (US$ Million) Table 125. MultiVir Recent Development Table 126. Research Programs/Design for This Report Table 127. Key Data Information from Secondary Sources Table 128. Key Data Information from Primary Sources List of Figures Figure 1. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type: 2020 VS 2027 Figure 2. Monoclonal Antibodies Features Figure 3. Checkpoint Inhibitors Features Figure 4. Oncoloytic Viral Therapies and Cancer Vaccines Features Figure 5. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2020 VS 2027 Figure 6. Lung Cancer Case Studies Figure 7. Breast Cancer Case Studies Figure 8. Colorectal Cancer Case Studies Figure 9. Melanoma Case Studies Figure 10. Prostate Cancer Case Studies Figure 11. Head and neck Cancer Case Studies Figure 12. Ovarian Cancer Case Studies Figure 13. Pancreatic Cancer Case Studies Figure 14. Others Case Studies Figure 15. Oncolytic Virus Cancer Immunotherapy Report Years Considered Figure 16. Global Oncolytic Virus Cancer Immunotherapy Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 17. Global Oncolytic Virus Cancer Immunotherapy Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 18. Global Oncolytic Virus Cancer Immunotherapy Market Share by Regions: 2020 VS 2027 Figure 19. Global Oncolytic Virus Cancer Immunotherapy Market Share by Regions (2022-2027) Figure 20. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players in 2020 Figure 21. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2020 Figure 22. The Top 10 and 5 Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2020 Figure 23. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2016-2021) Figure 24. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2022-2027) Figure 25. North America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 26. North America Oncolytic Virus Cancer Immunotherapy Market Share by Type (2016-2027) Figure 27. North America Oncolytic Virus Cancer Immunotherapy Market Share by Application (2016-2027) Figure 28. North America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2016-2027) Figure 29. United States Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. Canada Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. Europe Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Type (2016-2027) Figure 33. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Application (2016-2027) Figure 34. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Country (2016-2027) Figure 35. Germany Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. France Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. U.K. Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Italy Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Russia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Nordic Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Type (2016-2027) Figure 43. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Application (2016-2027) Figure 44. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Region (2016-2027) Figure 45. China Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Japan Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. South Korea Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. India Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Australia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Latin America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Type (2016-2027) Figure 53. Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Application (2016-2027) Figure 54. Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2016-2027) Figure 55. Mexico Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Brazil Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Type (2016-2027) Figure 59. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Application (2016-2027) Figure 60. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Country (2016-2027) Figure 61. Turkey Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 62. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 63. UAE Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million) Figure 64. AstraZeneca Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 65. Amgen Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 66. F Hoffman-La Roche Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 67. Bristol-Myers Squibb Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 68. Novartis AG Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 69. Merck & Co., Inc. Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 70. Pfizer Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 71. Biovex Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 72. Cell Genesys Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 73. Crusade Laboratories Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 74. Genelux Corporation Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 75. Lokon Pharma Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 76. MultiVir Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2016-2021) Figure 77. Bottom-up and Top-down Approaches for This Report Figure 78. Data Triangulation Figure 79. Key Executives Interviewed

AstraZeneca Amgen F Hoffman-La Roche Bristol-Myers Squibb Novartis AG Merck & Co., Inc. Pfizer Biovex Cell Genesys Crusade Laboratories Genelux Corporation Lokon Pharma MultiVir